Visara Inc. confronts medium-likelihood capital depletion before its VIS-101 therapeutic reaches market, according to February 2026 risk assessment. The NovaBridge subsidiary targets wet age-related macular degeneration and diabetic macular edema, conditions affecting 2.25 million Americans and comparable populations across Europe and Asia.
Phase III ophthalmology trials demand $100-300 million over 3-5 years before FDA or EMA approval. Visara must fund development without revenue as global biotech financing contracts. Q4 2025 venture funding dropped 23% year-over-year to $8.2 billion per PitchBook, hitting early-stage ophthalmology particularly hard: 67% fail to secure Series B funding despite needing $50-80 million for proof-of-concept data.
VIS-101 targets a $7 billion global anti-VEGF market dominated by Regeneron's Eylea and Roche's Lucentis. Capturing 10% market share could yield $700 million peak sales across North America, Europe and Japan. Wet AMD affects 1.5 million in the U.S., with similar prevalence in aging European and East Asian populations. DME impacts 750,000 American diabetics, part of a 537 million global diabetic population.
Companies exhausting runway face asset fire-sales at 30-50% discounts or dilutive down-rounds surrendering 60-80% of economics. NovaBridge parent support remains uncertain. Corporate parents typically cap subsidiary injections at $20-40 million, insufficient to bridge VIS-101 to commercialization.
Strategic paths include Big Pharma partnerships providing $150-250 million upfront for 40-60% equity stakes. IPOs or SPAC mergers remain possible if markets recover, but 2025's drought—18 biotech IPOs versus 93 in 2021—signals continued difficulty across U.S., European and Asian exchanges.
The assessment assigns 70% confidence to capital depletion risk, reflecting uncertainties in development timelines, regulatory requirements across FDA, EMA and PMDA jurisdictions, and financing availability. The scenario underscores biotech's binary outcomes globally: breakthrough returns or total loss for international investor pools from Silicon Valley to Singapore.
Sources:
1 Globe Newswire, "NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the " (February 19, 2026)